Hypothesis: atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease.

Abstract:

:The results of numerous long-term, randomized trials show that statins significantly decrease the risks of myocardial infarction, stroke, and vascular death as well as total mortality. The benefits of statins on cardiovascular disease in patients who are not experiencing acute coronary syndromes generally become apparent only after about 2 years. In contrast, atorvastatin conferred an early clinical benefit in the lipid-lowering arm of the long-term Anglo Scandinavian Cardiac Outcomes Trial as well as early benefit on progression of atherosclerosis in the Reversal of Atherosclerosis with Aggressive Lipid Lowering trial. An unexpected finding at baseline in the prospective Interaction of Atorvastatin and Clopidogrel Study was that patients on atorvastatin had significantly decreased platelet activity compared with either patients on other statins or those taking no statins. Atorvastatin has protective effects against membrane lipid peroxidation at pharmacologic concentrations. These and other considerations contribute to the hypothesis that atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease.

authors

Novela C,Hennekens CH

doi

10.1177/107424840400900i109

keywords:

subject

Has Abstract

pub_date

2004-03-01 00:00:00

pages

61-3

issue

1

eissn

1074-2484

issn

1940-4034

journal_volume

9

pub_type

杂志文章,评审
  • Safety and efficacy outcomes of preoperative aspirin in patients undergoing coronary artery bypass grafting: a systematic review and meta-analysis.

    abstract:BACKGROUND:The administration of aspirin is traditionally discontinued prior to coronary artery bypass grafting (CABG), given a potential risk of excessive postoperative bleeding. Few studies have previously suggested the benefits of continuing aspirin until the time of surgery. The primary aim of this review is to eva...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1177/1074248413509026

    authors: Ma X,Ma C,Yun Y,Zhang Q,Zheng X

    更新日期:2014-01-01 00:00:00

  • Effects of pre- and postconditioning on arrhythmogenesis in the in vivo rat model.

    abstract::The antiarrhythmic potential of postconditioning in in vivo models remains poorly defined. We compared the effects of pre- and postconditioning on ventricular arrhythmogenesis against controls with and without reperfusion. Wistar rats (n = 40, 269 ± 3 g) subjected to ischemia (30 minutes)--reperfusion (24 hours) were ...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248413482183

    authors: Kolettis TM,Vilaeti AD,Tsalikakis DG,Zoga A,Valenti M,Tzallas AT,Papalois A,Iliodromitis EK

    更新日期:2013-07-01 00:00:00

  • Variations in plasma free radicals in patients with venous hypertension with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized trial.

    abstract::The aim of this study was to demonstrate whether HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides), was effective in improving levels of plasma free radicals (PFRs) in patients with chronic venous insufficiency (CVI) and venous microangiopathy. Patients were randomized into the treatment group, which received o...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1177/107424840200700107

    authors: Cesarone MR,Incandela L,DeSanctis MT,Belcaro G,Dugall M,Acerbi G

    更新日期:2002-01-01 00:00:00

  • MethotrexaTE THerapy in ST-Segment Elevation MYocardial InfarctionS: A Randomized Double-Blind, Placebo-Controlled Trial (TETHYS Trial).

    abstract:PURPOSE:Methotrexate is an anti-inflammatory drug that has been shown to have anti-ischemic effects. Our aim was to evaluate if methotrexate could reduce infarct size in patients with ST-segment elevation myocardial infarction (STEMI). METHODS:We randomly assigned patients with STEMI to receive either methotrexate or ...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/1074248417699884

    authors: Moreira DM,Lueneberg ME,da Silva RL,Fattah T,Gottschall CAM

    更新日期:2017-11-01 00:00:00

  • Regression of Atherosclerotic Plaques of Cholesterol-Fed Rabbits by Combined Chemotherapy With Paclitaxel and Methotrexate Carried in Lipid Core Nanoparticles.

    abstract::In previous studies, it was demonstrated that lipid core nanoparticles (LDE) resemble the low-density lipoprotein structure and carrying the antiproliferative agent paclitaxel (PTX) strongly reduced atherosclerosis lesions induced in rabbits by cholesterol feeding. Currently, the aim was to verify whether combining LD...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248418778836

    authors: Gomes FLT,Maranhão RC,Tavares ER,Carvalho PO,Higuchi ML,Mattos FR,Pitta FG,Hatab SA,Kalil-Filho R,Serrano CV Jr

    更新日期:2018-11-01 00:00:00

  • Antiarrhythmic and Arrhythmogenic Actions of Varying Levels of Extracellular Magnesium: Possible Cellular Basis for the Differences in the Efficacy of magnesium and Lidocaine in Torsade de Pointes.

    abstract::BACKGROUND: In recent years, there has been an increasing use of antiarrhythmic drugs that act predominantly by prolonging myocardial repolarization. An inevitable electrophysiologic consequence of these drugs is the development of torsade de pointes as a proarrhythmic reaction. Both intravenous lidocaine and magnesiu...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424849700200206

    authors: Takanaka C,Ogunyankin KO,Sarma JS,Singh BN

    更新日期:1997-04-01 00:00:00

  • Nicorandil, a Nitric Oxide Donor and ATP-Sensitive Potassium Channel Opener, Protects Against Dystrophin-Deficient Cardiomyopathy.

    abstract:BACKGROUND:Dystrophin-deficient cardiomyopathy is a growing clinical problem without targeted treatments. We investigated whether nicorandil promotes cardioprotection in human dystrophin-deficient induced pluripotent stem cell (iPSC)-derived cardiomyocytes and the muscular dystrophy mdx mouse heart. METHODS AND RESULT...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248416636477

    authors: Afzal MZ,Reiter M,Gastonguay C,McGivern JV,Guan X,Ge ZD,Mack DL,Childers MK,Ebert AD,Strande JL

    更新日期:2016-11-01 00:00:00

  • Exploring the Quality of Anticoagulant Prescribed for Patients With Atrial Fibrillation at the St John of God Hawkesbury District Health Centre, New South Wales, Australia.

    abstract:BACKGROUND:Limited data are available on the clinical management of atrial fibrillation (AF) and its outcomes from an Australian perspective. OBJECTIVE:To describe the appropriateness of antithrombotic prescribing for patients who presented with a diagnosis of AF to the Hawkesbury St John of God Hospital, New South Wa...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248418786264

    authors: Wertheimer G,Bereznicki LR

    更新日期:2019-01-01 00:00:00

  • The cycloxygenase 2 (COX-2) story: it's time to explain, not inflame.

    abstract::Despite initial promising reports that anti-inflammatory properties of cycloxygenase-2 (COX-2) inhibitors may confer anti-atherosclerosis effects and stabilize the atherosclerotic plaque, subsequent data from long-term clinical trials have shown that selective COX-2 inhibitors are associated with increased risk of car...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248407301172

    authors: Salinas G,Rangasetty UC,Uretsky BF,Birnbaum Y

    更新日期:2007-06-01 00:00:00

  • Inhaled Fasudil Lacks Pulmonary Selectivity in Thromboxane-Induced Acute Pulmonary Hypertension in Newborn Lambs.

    abstract:INTRODUCTION:Pulmonary hypertension (PH) is a potentially deadly disease for infants and adults with few existing medical interventions and no cure. In PH, increased blood pressure in the pulmonary artery eventually leads to heart failure. Fasudil, an antagonist of Rho-kinase, causes vasodilation leading to decreased s...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248418772814

    authors: Hanson SFL,Terry MH,Moretta DT,Power GG,Wilson SM,Alam F,Ahsan F,Blood AB,Giri PC

    更新日期:2018-09-01 00:00:00

  • Is the standard weight-based dosing of dobutamine for stress testing appropriate for patients of widely varying body mass index?

    abstract:BACKGROUND:Although a gradual increase in heart rate (HR) during dobutamine stress testing (DST) is desired, few data exists regarding whether this is similarly achieved in patients of widely varying body mass index (BMI). Whether difference in BMI contributes to variation in the hemodynamic and symptomatic response to...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248410384709

    authors: Kittipovanonth M,Bernheim AM,Scott CG,Barnes ME,Shub C,Pellikka PA

    更新日期:2011-06-01 00:00:00

  • Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies.

    abstract::The primary effect of ischemia is reduced aerobic adenosine triphosphate (ATP) formation in mitochondria. This triggers accelerated glycolysis and reduced cell pH, Ca(2+) accumulation, K(+) efflux, adenosine formation, and the clinical signs of ischemia: chest pain and a shift in the ST segment. Traditional therapies ...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/107424840400900104

    authors: Stanley WC

    更新日期:2004-09-01 00:00:00

  • The importance of considering trial design when interpreting clinical trial results.

    abstract:BACKGROUND:In recent decades, clinical trials have played an increasingly important role in determining how we practice. Trial results proving that a clinical finding poses risk have led to interventions that try to reduce risk. Clinical trials proving that a particular therapy provides better outcome than another ther...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424840000500103

    authors: Reiffel JA

    更新日期:2000-01-01 00:00:00

  • Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need.

    abstract::Acute medical illnesses are associated with a prolonged elevation in inflammatory markers that predisposes patients to thrombosis beyond the duration of their hospital stay. In parallel, both observational and randomized data have demonstrated a rate of postdischarge venous thromboembolic events that often exceeds tha...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248415601894

    authors: Korjian S,Daaboul Y,Halaby R,Goldhaber SZ,Cohen AT,Singh K,Susheela AT,Harrington RA,Hull RD,Hernandez AF,Gibson CM

    更新日期:2016-05-01 00:00:00

  • Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study.

    abstract:OBJECTIVE:To describe major events at follow up in octogenarian patients with atrial fibrillation (AF) according to anticoagulant treatment: direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs). METHODS:A total of 578 anticoagulated patients aged ≥80 years with AF were included in a prospective, obse...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1177/1074248420916316

    authors: Ortiz MR,Muñiz J,Esteve-Pastor MA,Marín F,Roldán I,Cequier A,Martínez-Sellés M,Saldivar HG,Bertomeu V,Anguita M

    更新日期:2020-07-01 00:00:00

  • Diabetes, heart rate, and mortality.

    abstract::A large body of evidence indicates that a persistently high heart rate is associated with a significant risk for higher mortality and sudden death in individuals with a variety cardiovascular disorders, as well as in the general population. Heart rates elevated beyond a certain threshold have been found to be a risk f...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/107424840200700208

    authors: Singh N

    更新日期:2002-04-01 00:00:00

  • Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC.

    abstract:BACKGROUND:Fluvastatin is an inhibitor of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, effectively lowering serum cholesterol concentrations. A high-performance liquid chromatography (HPLC) assay was developed that determined the pharmacokinetics of fluvastatin in healthy individuals after administrat...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1177/107424840100600205

    authors: Siekmeier R,Lattke P,Mix C,Park JW,Jaross W

    更新日期:2001-04-01 00:00:00

  • Use of Lipid Drugs With Acute Myocardial Infarction Patients: An Examination of Physician Prescribing Behaviors.

    abstract::BACKGROUND: Clinical trials have shown that the use of lipid-lowering agents in postmyocardial infarction (MI) patients reduces rates of subsequent coronary events, reduces coronary artery bypass surgery rates, and improves survival. Physician decisions to prescribe lipid-lowering drugs is influenced by a number of pa...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424849800300303

    authors: Khan M,Mukkamala A,Taylor DK,Espinosa A,Duff J

    更新日期:1998-07-01 00:00:00

  • Persistence of Atrial Fibrillation After Its Induction-Importance of the Duration and Dispersion of Atrial Refractoriness and Electrical Remodeling.

    abstract::BACKGROUND: The electrophysiologic mechanisms of the persistence of atrial fibrillation (AF) after its initiation are not well understood. Therefore, the electrophysiologic characteristics of the right atrium were evaluated in an acute, pacing-induced model of AF in the pig in order to identify parameters associated w...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424849900400206

    authors: Rahme MM,Cotter B,Leistad E,Subudhayangkul S,Wadhwa M,Ungab G,Feld GK

    更新日期:1999-04-01 00:00:00

  • Sarcoplasmic reticulum adenosine triphosphatase overexpression in the L-type Ca2+ channel mouse results in cardiomyopathy and Ca2+ -induced arrhythmogenesis.

    abstract:BACKGROUND:Overexpression of the L-type voltage-dependent calcium channel alpha(1C)-subunit (L-VDCC OE) in transgenic mice results in adaptive hypertrophy followed by a maladaptive phase associated with a decrease in sarcoplasmic reticulum adenosine triphosphatase (SERCA)2a expression at 8 to 10 months of age. Overexpr...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424840501000404

    authors: Rubio M,Bodi I,Fuller-Bicer GA,Hahn HS,Periasamy M,Schwartz A

    更新日期:2005-12-01 00:00:00

  • The influence of extracellular acidosis on the effect of IKr blockers.

    abstract:BACKGROUND:Myocardial infarction causes the acidification of the cellular environment and the resultant acidosis maybe arrhythmogenic. The effect of acidosis on the action of antiarrhythmic drugs, an important issue in the antiarrhythmic drug therapy after myocardial infarction, remains to be studied. METHODS:To evalu...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424840501000108

    authors: Lin C,Ke X,Cvetanovic I,Ranade V,Somberg J

    更新日期:2005-03-01 00:00:00

  • Chronic Administration of Catestatin Improves Autonomic Function and Exerts Cardioprotective Effects in Myocardial Infarction Rats.

    abstract::Catestatin (CST), which is emerging as a novel cardiac modulator, can protect the heart against excessive sympathetic drive in hypertensive cardiomyopathy. The aim of this study is to investigate whether exogenous CST decreases excessive cardiac sympathetic drive and improves autonomic function and exerts cardioprotec...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248416628676

    authors: Wang D,Liu T,Shi S,Li R,Shan Y,Huang Y,Hu D,Huang C

    更新日期:2016-11-01 00:00:00

  • Repurposing From Oncology to Cardiology: Low-Dose 5-Azacytidine Attenuates Pathological Cardiac Remodeling in Response to Pressure Overload Injury.

    abstract:INTRODUCTION:Recent evidence suggests that transcriptional reprogramming is involved in the pathogenesis of cardiac remodeling (cardiomyocyte hypertrophy and fibrosis) and the development of heart failure. 5-Azacytidine (5aza), an inhibitor of DNA methylation approved for hematological malignancies, has previously demo...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248420979235

    authors: Russell-Hallinan A,Neary R,Watson CJ,Baugh JA

    更新日期:2020-12-02 00:00:00

  • Increasing doses of simvastatin versus combined ezetimibe/simvastatin: effect on circulating endothelial progenitor cells.

    abstract:BACKGROUND:Patients with coronary artery disease (CAD) should be treated with statins to attain very low cholesterol levels, in order to reduce cardiovascular adverse events. More than 70% of these patients do not reach the appropriate cholesterol goal despite moderate statin doses. However, it is not known whether the...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/1074248413489771

    authors: Pesaro AE,Serrano CV Jr,Katz M,Marti L,Fernandes JL,Parra PR,Campos AH

    更新日期:2013-09-01 00:00:00

  • Molecular Delivery System for Antisense Oligonucleotides: Enhanced Effectiveness of Antisense Oligonucleotides by HVJ-liposome Mediated Transfer.

    abstract::BACKGROUND: The effectiveness of antisense oligodeoxynucleotides for in vitro and in vivo studies is limited by a low efficiency of cellular uptake and instability due to degradation by nucleases. To overcome some of these problems, we recently developed a transfer method that utilizes inactivated Sendai virus (hemagg...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424849700200308

    authors: Morishita R,Gibbons GH,Horiuchi M,Nakajima M,Ellison KE,Lee W,Kaneda Y,Ogihara T,Dzau VJ

    更新日期:1997-07-01 00:00:00

  • Nonplatelet effects of aspirin during acute coronary occlusion: electrophysiologic and cation alterations in ischemic myocardium.

    abstract:BACKGROUND:Mortality after acute myocardial ischemia has been reduced by aspirin (ASA) but mechanisms other than the antiplatelet effect have not been established. This article evaluates an antiarrhythmic action during sympathetic stimulation in the intact anesthetized dog with and without ischemia. METHODS AND RESULT...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1053/XV.2000.5492

    authors: Shehadeh AA,Arena J,Moschos CB,Regan TJ

    更新日期:2000-04-01 00:00:00

  • Effects of Sotalol on the Circadian Rhythmicity of Heart Rate and QT Intervals With a Noninvasive Index of Reverse-Use Dependency.

    abstract::BACKGROUND: The effects of sotalol on the 24-hour profile of the QT interval relative to that of the heart rate (HR) may be helpful in determining the time course of the drug's action in controlling cardiac arhythmias. This has not been previously determined. Thus, the objective of the current study was to evaluate th...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424849900400104

    authors: Sharma PP,Sarma JS,Singh BN

    更新日期:1999-01-01 00:00:00

  • Reduction of Myocardial Necrosis After Glycosaminoglycan Administration: Effects of a Single Intravenous Administration of Heparin or N-Acetylheparin 2 Hours Before Regional Ischemia and Reperfusion.

    abstract::BACKGROUND: We determined if a single administration of heparin or nonanticoagulant N-acetylheparin could reduce myocardial injury resulting from a 90-minute occlusion of the left circumflex coronary artery (LCX) and 6 hours of reperfusion in the anesthetized canine. METHODS AND RESULTS: Heparin (2 mg/kg), N-acetylhep...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1053/jcpt.1996.0219

    authors: Gralinski MR,Driscoll EM,Friedrichs GS,DeNardis MR,Lucchesi BR

    更新日期:1996-07-01 00:00:00

  • Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure.

    abstract:BACKGROUND:epidemiologic studies indicate that elevated heart rate (HR) is an independent risk factor for mortality and morbidity in patients (pts) with chronic heart failure (CHF). Clinical trials with β-blockers suggest that HR reduction is an important mechanism of their benefit in pts with stable CHF. Pharmacologic...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/1074248410370326

    authors: Sarullo FM,Fazio G,Puccio D,Fasullo S,Paterna S,Novo S,Di Pasquale P

    更新日期:2010-12-01 00:00:00

  • Inhibition of Atherosclerosis Progression, Intimal Hyperplasia, and Oxidative Stress by Simvastatin and Ivabradine May Reduce Thoracic Aorta's Stiffness in Hypercholesterolemic Rabbits.

    abstract:AIMS:This study aims to evaluate atherosclerosis, oxidative stress, and arterial stiffness attenuation by simvastatin and ivabradine in hyperlipidemic rabbits. METHODS AND RESULTS:Forty rabbits were randomly divided into 4 groups: atherogenic diet (group C), atherogenic diet plus simvastatin (group S), atherogenic die...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248415617289

    authors: Koniari I,Mavrilas D,Apostolakis E,Papadimitriou E,Papadaki H,Papalois A,Poimenidi E,Xanthopoulou I,Hahalis G,Alexopoulos D

    更新日期:2016-07-01 00:00:00